Discoid lupus erythematosus
MONDO:0019558A chronic, autoimmune skin condition that manifests with a red, scaling rash, most often found on the face, ears, and scalp; these lesions often lead to permanent scarring and dyspigmentation. Patients may have lesions with or without other symptoms or antibodies suggestive of systemic lupus erythematosus (SLE).
Also known as: DLE
52 clinical trials for this condition and its sub-types, 17 tagged with Discoid lupus erythematosus itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New pill could ease lupus skin rashes in major trial
Disease control Recruiting nowThis study tests a drug called enpatoran for people with lupus who have active skin rashes or lesions. About 202 participants will take either enpatoran or a placebo twice daily for 24 weeks, alongside their usual treatments. The goal is to see if the drug can significantly impro…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill aims to calm lupus skin flares in major trial
Disease control Recruiting nowThis study tests an experimental pill called enpatoran for people with lupus who have active skin rashes. About 202 participants will receive either the drug or a placebo for 24 weeks, while continuing their usual treatments. The goal is to see if enpatoran can significantly redu…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Lupus drug continuation trial offers hope for disease control
Disease control Recruiting nowThis study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…
Phase 4 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Old malaria drug may tame lupus skin flares
Disease control Recruiting nowThis study tests whether quinacrine, a medication originally used for malaria, can safely reduce skin rashes and sores in people with cutaneous lupus erythematosus (CLE). Participants receive either quinacrine or a placebo for 12 weeks, then all receive quinacrine for another 12 …
Phase 2 • Sponsor: Victoria Werth • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill could tame skin lupus flares
Disease control Recruiting nowThis study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The mai…
Phase 2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
10,000 lupus patients needed for landmark online study
Knowledge-focused Recruiting nowThis study is a fully online registry for adults and children with lupus. Participants fill out surveys every six months about their symptoms, treatments, and quality of life. The goal is to collect real-world data to improve care and guide future research. No travel or clinic vi…
Sponsor: Lupus Foundation of America • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC